Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EBS 
Emergent Biosolutions Inc (EBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EBS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.1% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 344.66M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 3 | Beta 2.11 | 52 Weeks Range 4.02 - 15.10 | Updated Date 06/29/2025 |
52 Weeks Range 4.02 - 15.10 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.63% | Operating Margin (TTM) 22.68% |
Management Effectiveness
Return on Assets (TTM) -1.61% | Return on Equity (TTM) -21.63% |
Valuation
Trailing PE - | Forward PE 42.37 | Enterprise Value 861264201 | Price to Sales(TTM) 0.36 |
Enterprise Value 861264201 | Price to Sales(TTM) 0.36 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA 8.17 | Shares Outstanding 54277800 | Shares Floating 52797671 |
Shares Outstanding 54277800 | Shares Floating 52797671 | ||
Percent Insiders 2.83 | Percent Institutions 67.2 |
Analyst Ratings
Rating 2 | Target Price 13.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Emergent Biosolutions Inc
Company Overview
History and Background
Emergent BioSolutions Inc. was founded in 1998 as BioPort Corporation and renamed Emergent BioSolutions in 2004. It focuses on public health threats through its development and manufacturing of vaccines and therapeutics.
Core Business Areas
- Biodefense: Develops and delivers medical countermeasures against biological and chemical threats.
- Commercial: Provides products and services to address emerging infectious diseases and other public health needs.
- Contract Development and Manufacturing (CDMO): Offers contract manufacturing services to pharmaceutical and biotechnology companies.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives. The organizational structure includes business units focused on biodefense, commercial products, and CDMO services.
Top Products and Market Share
Key Offerings
- Anthrax Vaccines (BioThrax & AV7909): BioThrax is an anthrax vaccine. AV7909 is the next generation of anthrax vaccine. Competitors are limited due to government contracts.
- Smallpox Vaccine (ACAM2000): ACAM2000 is a live virus smallpox vaccine. Competitors are limited due to government contracts.
- NARCAN Nasal Spray: NARCAN Nasal Spray is a naloxone hydrochloride nasal spray used to treat opioid overdose. Competitors include generic naloxone products.
Market Dynamics
Industry Overview
The biodefense market is driven by government contracts and public health concerns. The CDMO market is competitive and driven by pharmaceutical companies outsourcing manufacturing.
Positioning
Emergent is a key player in the biodefense market, benefiting from government contracts. In the CDMO market, it competes with larger contract manufacturers.
Total Addressable Market (TAM)
The TAM for biodefense and CDMO combined is estimated to be in the billions of USD. Emergent holds a significant share of the biodefense market, but has less share of the CDMO market.
Upturn SWOT Analysis
Strengths
- Strong relationships with government agencies
- Established presence in the biodefense market
- Specialized manufacturing capabilities
Weaknesses
- Dependence on government contracts
- Past Manufacturing issues and contract termination
- High debt levels
Opportunities
- Expanding into new geographic markets
- Developing new products for emerging infectious diseases
- Growing CDMO business through strategic partnerships
Threats
- Changes in government funding priorities
- Increased competition in the CDMO market
- Regulatory challenges
Competitors and Market Share
Key Competitors
- SIGA (SIGA)
- CBRX (CBRX)
- GOVX (GOVX)
Competitive Landscape
Emergent faces competition from other biodefense companies and CDMO providers. Its government relationships and specialized manufacturing capabilities are key advantages.
Major Acquisitions
Adapt Pharma
- Year: 2018
- Acquisition Price (USD millions): 735
- Strategic Rationale: Expanded Emergent's commercial product portfolio with NARCAN Nasal Spray for opioid overdose.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to the nature of government contracts and manufacturing issues.
Future Projections: Future growth depends on securing new government contracts, expanding the CDMO business, and successful commercialization of new products. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include restructuring efforts to reduce costs and refocus on core businesses. Efforts to restore good reputation from previous manufacturing errors.
Summary
Emergent Biosolutions is facing challenges with high debt, manufacturing issues, and dependence on government contracts, leading to volatile financial performance and negative shareholder returns. Their strengths are established relationships with government agencies and specialized manufacturing abilities, offering opportunity to capitalize on emerging diseases and expanding CDMO partnerships. Success will rely on securing contracts, resolving manufacturing quality issues, and managing debt. The company's financial stability and reputation are currently weak, requiring a strategic turnaround.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Emergent Biosolutions Inc
Exchange NYSE | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2006-11-15 | CEO, President & Director Mr. Joseph C. Papa Jr., M.B.A., R.Ph. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 900 | |
Full time employees 900 | |||
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.